Aligos Therapeutics Inc share price logo

Aligos Therapeutics Inc Share Price

NASDAQ: ALGS

Small Cap

$9.41

-0.79

(-7.75%)

as on

Aligos Therapeutics Inc Stock Performance

as on September 16, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $9.29
    $10.28
    downward going graph

    1.28%

    Downside

    9.25%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.76
    $46.8
    downward going graph

    60.04%

    Downside

    397.34%

    Upside

    downward going graph

Aligos Therapeutics Inc share price movements today

Previous Close
$10.20
Open
$10.18
Volume
258.7K
Day's Low - High
$9.29 - $10.28
52 Week Low - High
$3.76 - $46.8

Aligos Therapeutics Inc Historical Returns

1 Month Return
+ 32.47 %
3 Month Return
+ 32.3 %
1 Year Return
-31.08 %
3 Year Return
-69.32 %
5 Year Return
0 %

Aligos Therapeutics Inc Stock Fundamentals & Key Indicators

Check Aligos Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$70.9M

EPS (TTM)

-7.88

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-13.35

Industry PE ratio

-3.8535542168674697

P/B Ratio

0

PEG Ratio

0

EBITDA

-77.6M

Revenue (TTM)

3.2M

Profit Margin

0.00%

Return On Equity TTM

0.00%

Aligos Therapeutics Inc Stock Valuation

Track how Aligos Therapeutics Inc P/E has moved over time to understand its valuation trends.

Aligos Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 15, 2025

Today (-13.35x)

September 15, 2025

Industry (-3.85x)

September 15, 2025

Highest (-0.30x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -13.35x

Aligos Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aligos Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Aligos Therapeutics Inc image
Aligos Therapeutics Inc
BUY$70.9MNA-13.350.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$61.1B256.98%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$38.7BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$101.1B47.85%28.0731.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$59.4B-3.43%14.1131.37%

Stock Returns calculator for Aligos Therapeutics Inc Stock including INR - Dollar returns

The Aligos Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Aligos Therapeutics Inc investment value today

Current value as on today

₹68,566

Returns

₹31,434

(-31.43%)

Returns from Aligos Therapeutics Inc Stock

₹36,419 (-36.42%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on Aligos Therapeutics Inc Stock

Based on 8 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 8 analysts, 75% of analysts recommend a 'BUY' rating for Aligos Therapeutics Inc. Average target price of $80.25

Aligos Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Aligos Therapeutics Inc.

What analysts predicted

88.27%UPSIDE

Target Price

$80.25

Current Price

$9.41

Analyzed by

8 Analysts

Target

$80.25

Aligos Therapeutics Inc target price $80.25, a slight upside of 88.27% compared to current price of $9.41. According to 8 analysts rating.

Aligos Therapeutics Inc Stock's Interest Amongst Investors

Search interest for Aligos Therapeutics Inc Stock has increased by 109% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:109% versus previous 30 day period

Aligos Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
2
6
3
2
0
1
1
0
0
0
Gross Profit
1
6
2
1
0
0
1
0
0
0
Operating Income
-21
-19
-19
-25
-22
-26
-20
-20
-19
-18
EBITDA
-23
-18
-18
-27
-21
-26
-19
-19
-18
-15
Interest Expense
1
-
-
1
12
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-22
-18
-18
-27
-34
5
-19
-82
43
-15
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-22
-18
-18
-27
-34
5
-19
-82
43
-15
Net Profit Margin
-843.00%
-272.89%
-556.99%
-1040.36%
-3535.80%
477.00%
-1517.65%
-13060.41%
13854.66%
-1643.83%

Aligos Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-10
4
13
15
3
Gross Profit
-1
-2
-10
4
13
12
3
Operating Income
-13
-54
-97
-128
-97
-88
-89
EBITDA
-12
-49
-94
-124
-93
-85
-89
Interest Expense
-
1
10
0
1
-
-
Depreciation
1
2
3
3
3
3
2
Income Before Tax
-13
-52
-108
-128
-95
-86
-130
Income Tax Expense
0
0
0
0
0
0
0
Net Income
-13
-52
-108
-128
-96
-87
-131
Net Profit Margin
0.00%
0.00%
1029.04%
-2944.07%
-690.63%
-564.61%
-3326.01%

Aligos Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-18
-18
-27
-34
5
-19
-82
43
-15
Operating Cash Flow
-13
-20
-22
-22
-19
-20
-18
-20
-15
Investing Cash Flow
25
0
0
-88
39
10
19
-44
-39
Financing Cash Flow
0
0
87
0
0
0
0
101
0
Change in Cash
11
-20
65
-111
20
-9
1
36
-55

Aligos Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-52
-108
-128
-96
-87
-131
Operating Cash Flow
-46
-74
-115
-79
-78
-80
Investing Cash Flow
6
32
3
-26
44
-18
Financing Cash Flow
85
192
78
0
88
0
Change in Cash
45
150
-33
-105
54
-98

Global Institutional Holdings in Aligos Therapeutics Inc

Funds
Holdings
Adage Capital Partners Gp LLC
7.6%
Deep Track Capital, LP
7.26%
Alyeska Investment Group, L.P.
6.74%
Woodline Partners LP
5.16%
Heights Capital Management Inc
3.95%
See all

Insights on Aligos Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 311.0K → 965.0K (in $), with an average increase of 67.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.3% return, outperforming this stock by 100.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 118.7% return, outperforming this stock by 183.8%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, ALGS stock has moved down by -9.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 43.08M → -15.86M (in $), with an average decrease of 136.8% per quarter

About Aligos Therapeutics Inc

aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-㟠agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.
OrganisationAligos Therapeutics Inc
HeadquartersOne Corporate Drive, South San Francisco, CA, United States, 94080
IndustryHealth Technology
CEODr. Lawrence M. Blatt MBA, Ph.D.
E-voting on sharesClick here to vote

Key Management of Aligos Therapeutics Inc

Name

Title

Ms. Lesley Ann Calhoun CPA

Executive VP, CFO & COO

Dr. Julian A. Symons DPHIL

Executive VP & Chief Scientific Officer

Ms. Kristina Engeseth M.B.A.

Senior VP and Head of People & Culture

Dr. David B. Smith Ph.D.

Executive VP & Head of Chemical Operations

Dr. Tse-I Lin Ph.D.

Senior VP of Early Compound Development & Belgian Site Head

Dr. Hardean E. Achneck M.D.

Executive VP & Chief Medical Officer

Dr. Lawrence M. Blatt MBA, Ph.D.

CEO, President & Chairman of the Board

Ms. Laura Kavanaugh

VP & Head of Legal

Dr. Sushmita M. Chanda DABT, Ph.D.

Executive Vice President & Chief Development Officer

Dr. Kieron Wesson Ph.D.

Vice President & Head of Chemistry Manufacturing Controls

FAQs

What is Aligos Therapeutics Inc share price today?

Aligos Therapeutics Inc share price today is $9.41 as on at the close of the market. Aligos Therapeutics Inc share today touched a day high of $10.28 and a low of $9.29.

What is the 52 week high and 52 week low for Aligos Therapeutics Inc share?

Aligos Therapeutics Inc share touched a 52 week high of $46.8 on and a 52 week low of $3.76 on . Aligos Therapeutics Inc stock price today i.e. is closed at $9.41,which is 79.89% down from its 52 week high and 150.27% up from its 52 week low.

What is Aligos Therapeutics Inc's market capitalisation today?

Aligos Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Aligos Therapeutics Inc Stock (ALGS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Aligos Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aligos Therapeutics Inc Shares that will get you 0.1594 shares as per Aligos Therapeutics Inc share price of $9.41 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Aligos Therapeutics Inc Stock (ALGS) from India?

Indian investors can start investing in Aligos Therapeutics Inc (ALGS) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Aligos Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Aligos Therapeutics Inc share’s latest price of $9.41 as on September 16, 2025 at 1:29 am IST, you will get 1.0627 shares of Aligos Therapeutics Inc. Learn more about fractional shares .